Notification Number: 2015/495/UK

British Pharmacopoeia 2016

Date received : 24/08/2015 End of Standstill : 25/11/2015

Message

Message 001

Communication from the Commission - TRIS/(2015) 02699

Directive 98/34/EC

Notificación - Oznámení - Notifikation - Notifizierung - Teavitamine - Γνωστοποίηση - Notification - Notifica - Pieteikums - Pranešimas - Bejelentés - Notifika - Kennisgeving - Zawiadomienie - Notificacão - Hlásenie-Obvestilo - Ilmoitus - Anmälan - Нотификация : 2015/0495/UK - Notificare.

No abre el plazo - Nezahajuje odklady - Fristerne indledes ikke - Kein Fristbeginn - Viivituste perioodi ei avata - Καμμία έναρξη προθεσμίας - Does not open the delays - N'ouvre pas de délais - Non fa decorrere la mora - Neietekmē atlikšanu - Atidėjimai nepradedami - Nem nyitja meg a késéseket - Ma' jiftaħx il-perijodi ta' dawmien - Geen termijnbegin - Nie otwiera opóźnień - Nao inicia o prazo - Neotvorí oneskorenia - Ne uvaja zamud - Мääräaika ei ala tästä - Inleder ingen frist - Не се предвижда период на прекъсване - Nu deschide perioadele de stagnare - Nu deschide perioadele de stagnare.

(MSG: 201502699.EN)

1. Structured Information Line

MSG 001 IND 2015 0495 UK EN 24-08-2015 UK NOTIF

2. Member State

UK

3. Department Responsible

Department for Business, Innovation and Skills European Reform Directorate 1 Victoria Street, London, SW1H 0ET.

Email: 9834@bis.gsi.gov.uk.

3. Originating Department

Medicines and Healthcare products Regulatory Agency (MHRA) British Pharmacopoeia Commission 151 Buckingham Palace Road London



EUROPEAN COMMISSION GROWTH DIRECTORATE-GENERAL

Single Market for goods
Prevention of Technical Barriers

SW1W 9SZ

4. Notification Number

2015/0495/UK - C30P

5. Title

British Pharmacopoeia 2016

6. Products Concerned

Various pharmaceutical products

7. Notification Under Another Act

-

8. Main Content

New and revised national standards for the British Pharmacopoeia 2016 and changes to implement the 8th Edition and Supplements of the European Pharmacopoeia

The following monographs are new additions to the British Pharmacopoeia 2016

Formulated Preparations: Specific Monographs

Abacavir and Lamivudine Tablets

Abacavir, Zidovudine and Lamivudine Tablets

Gastro-resistant Acamprosate Tablets

Bendroflumethiazide Oral Suspension

Carvedilol Tablets

Ceftazidime Eye Drops

Clotrimazole Eye Drops

Clotrimazole Vaginal Tablets

Diamorphine Tablets

Estradiol Vaginal Tablets

Etynodiol Tablets

Fluconazole Capsules

Fluconazole Infusion

Fluconazole Oral Suspension

Flumetasone and Clioquinol Ear Drops

Flupentixol Tablets

Fluticasone and Salmeterol Pressurised Inhalation Powder, pre-dispensed

Fluticasone and Salmeterol Pressurised Inhalation, Suspension

Interferon Beta-1a Injection

Ketoconazole Cream

Ketoconazole Shampoo

Lorazepam Oral Solution

Miconazole Eye Drops

Olanzapine Tablets

Orodispersible Olanzapine Tablets

Olmesartan Tablets

Soluble Prednisolone Tablets



Rizatriptan Tablets
Orodispersible Rizatriptan Tablets
Prolonged-release Sodium Valproate Capsules
Prolonged-release Sodium Valproate Tablets
Terbinafine Tablets
Vecuronium Bromide for Injection
Zidovudine Infusion

Herbal Drugs, Herbal Drug Preparations and Herbal Medicinal Products

Holy Basil Leaf Phellodendron Amurense Bark Phellodendron Chinense Bark

Technical Changes

Medicinal and Pharmaceutical Substances

Nicorandil

Phenelzine Sulfate

Formulated Preparations: Specific Monographs

Abacavir Tablets Adapalene Cream Adapalene Gel

Alendronic Acid Tablets

Alfuzosin Tablets

Prolonged-release Alfuzosin Tablets

Aminophylline Injection Aminophylline Tablets

Prolonged-release Aminophylline Tablets

Carbimazole Tablets

Chloral Hydrate Oral Solution

Clobazam Oral Suspension

Clobazam Tablets

Clonazepam Tablets

Clonidine Tablets

Clotrimazole Pessaries

Codeine Phosphate Oral Solution

Desmopressin Tablets

Dexamethasone Sodium Phosphate Injection

Prolonged-release Dipyridamole Capsules

Dipyridamole Infusion

Doxorubicin Injection

Econazole Pessaries

Enoxaparin Sodium Injection

Ergocalciferol Injection

Ethinylestradiol Tablets

Paediatric Ferrous Sulfate Oral Solution

Glimepiride Tablets

Goserelin Implants



EUROPEAN COMMISSION GROWTH DIRECTORATE-GENERAL

Single Market for goods
Prevention of Technical Barriers

Heparin Injection

Hydroxychloroquine Tablets

Hydroxyzine Oral Solution

Kaolin Mixture

Kaolin and Morphine Mixture

Lamotrigine Tablets

Dispersible Lamotrigine Tablets

Levonorgestrel Tablets

Lisinopril Oral Solution

Lymecycline Capsules

Aromatic Magnesium Carbonate Mixture

Magnesium Hydroxide Mixture

Magnesium Sulfate Mixture

Magnesium Trisilicate Mixture

Melphalan Injection

Methotrexate Injection

Methotrexate Oral Solution

Morphine Sulfate Injection

Naloxone Injection

Omeprazole Oral Suspension

Oxymetholone Tablets

Liquid Paraffin Oral Emulsion

Liquid Paraffin and Magnesium Hydroxide Oral Emulsion

Paroxetine Tablets

Phenobarbital Elixir

Paediatric Phenobarbital Oral Solution

Phenobarbital Tablets

Phenobarbital Sodium Tablets

Phentolamine Injection

Phenytoin Capsules

Phenytoin Oral Suspension

Phenytoin Tablets

Potassium Citrate Mixture

Prednisolone Oral Solution

Primidone Oral Suspension

Primidone Tablets

Ramipril Capsules

Ramipril Tablets

Simvastatin Oral Suspension

Sodium Bicarbonate Oral Solution

Compound Sodium Chloride Mouthwash

Sodium Chloride Oral Solution

Sodium Valproate Oral Solution

Sodium Valproate Tablets

Gastro-resistant Sodium Valproate Tablets

Sumatriptan Injection

Sumatriptan Nasal Spray

Sumatriptan Tablets

Vinblastine Injection

Vincristine Injection

Zidovudine Capsules

Zidovudine Tablets

Fax: +32 229 98043

email: grow-dir83-189-central@ec.europa.eu

Zidovudine and Lamivudine Tablets Zuclopenthixol Decanoate Injection 9. Brief Statement of Grounds Protection of health and welfare 10. Reference Documents - Basic Texts Basic Texts have been forwarded within the framework of a previous notification: 2014/404/UK 11. Invocation of the Emergency Procedure No 12. Grounds for the Emergency 13. Confidentiality 14. Fiscal measures No 15. Impact assessment 16. TBT and SPS aspects TBT aspect No - The draft has no significant impact on international trade SPS aspect No - The draft has no significant impact on international trade ***** **European Commission** Contact point Directive 98/34